Ashland has fully integrated its research and development facilities across the globe to better support true-to-life consumer and clinical evaluations of its personal care ingredient portfolio.
“Moving clinical testing to the areas consumers will use our ingredients has been a priority for Ashland for more than five years,” said Linda Foltis, vice president of care specialties research and development (R&D), Ashland Specialty Ingredients. “Consumer and clinical panels can now be based on a true representation of the population using prototype formulations that contain our ingredients. Ingredients and formulation architecture can be further evaluated based on actual climate, geography, and environmental conditions. At the same time, Ashland can evaluate how ingredients, incorporated into prototype formulations, are most likely to be used by consumers in real-world conditions. This comprehensive evaluation system allows us to R&D facilities across globe gain insights into the way consumers experience our ingredients and formulation architecture.”
Ashland is conducting consumer panel and clinical studies in major markets, such as Shanghai, China; Mumbai, India; the Netherlands; and the United States. Taking into account out-of-the-laboratory variables, such as environmental effects, Ashland now offers a more complete picture of the performance of its ingredient portfolio in markets around the world.
